126 related articles for article (PubMed ID: 4042071)
1. A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration.
Lokich JJ; Curt G
Cancer; 1985 Nov; 56(10):2391-4. PubMed ID: 4042071
[TBL] [Abstract][Full Text] [Related]
2. 5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study.
Lokich JJ; Phillips D; Green R; Paul S; Sonneborn H; Zipoli TE; Curt G
Cancer; 1985 Nov; 56(10):2395-8. PubMed ID: 4042072
[TBL] [Abstract][Full Text] [Related]
3. Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system.
Lokich J; Bothe A; Zipoli T; Green R; Sonneborn H; Paul S; Philips D
J Clin Oncol; 1983 Jan; 1(1):24-8. PubMed ID: 6668481
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture. Phase I trial of 14-day continuous ambulatory infusion.
Lokich J; Bern M; Anderson N; Wallach S; Moore C; Beauchamp K; Williams D
Cancer; 1989 Mar; 63(5):822-4. PubMed ID: 2914289
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
7. The prevention of methotrexate toxicity by thymidine infusions in humans.
Ensminger WD; Frei E
Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
Lokich J; Corkery J
Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
[TBL] [Abstract][Full Text] [Related]
9. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
Smit EF; Willemse PH; Sleijfer DT; Uges DR; Postmus PE; Meijer S; Terheggen PM; Mulder NH; de Vries EG
J Clin Oncol; 1991 Jan; 9(1):100-10. PubMed ID: 1985158
[TBL] [Abstract][Full Text] [Related]
11. The safety of administration of massive doses of methotrexate (50 g) with equimolar citrovorum factor rescue in adult patients.
Reggev A; Djerassi I
Cancer; 1988 Jun; 61(12):2423-8. PubMed ID: 3259154
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
13. Infusional carboplatin. Phase I studies of 5-day and 14-day infusions.
Lokich J; Anderson N; Bern M; Zipli T; Gonsalves L; Moore C
Cancer; 1991 Jul; 68(1):68-71. PubMed ID: 2049755
[TBL] [Abstract][Full Text] [Related]
14. Test dose for predicting high-dose methotrexate infusions.
Kerr IG; Jolivet J; Collins JM; Drake JC; Chabner BA
Clin Pharmacol Ther; 1983 Jan; 33(1):44-51. PubMed ID: 6848298
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions.
Parker RI; Forman EN; Krumm KF; Abeel MJ; Martin HF
Ther Drug Monit; 1986; 8(4):393-9. PubMed ID: 3469802
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies.
Blumenreich MS; Woodcock TM; Richman SP; Jones MK; Gentile PS; Kubota TT; Allegra JC
Cancer; 1985 Jul; 56(2):256-8. PubMed ID: 4005796
[TBL] [Abstract][Full Text] [Related]
17. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
19. Theoretically required urinary flow during high-dose methotrexate infusion.
Sasaki K; Tanaka J; Fujimoto T
Cancer Chemother Pharmacol; 1984; 13(1):9-13. PubMed ID: 6733846
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion.
Lokich JJ
Cancer Treat Rep; 1980; 64(8-9):905-8. PubMed ID: 6256073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
